The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer

IF 8.3 2区材料科学 Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY

ACS Applied Materials & Interfaces Pub Date : 2024-09-18 DOI:10.3389/fimmu.2024.1455469

Carla Fernanda Furtado Gardani, Fernando Mendonça Diz, Luísa Brandalise Dondé, Liliana Rockenbach, Stefan Laufer, Fernanda Bueno Morrone

{"title":"The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer","authors":"Carla Fernanda Furtado Gardani, Fernando Mendonça Diz, Luísa Brandalise Dondé, Liliana Rockenbach, Stefan Laufer, Fernanda Bueno Morrone","doi":"10.3389/fimmu.2024.1455469","DOIUrl":null,"url":null,"abstract":"Purines and pyrimidines are signaling molecules in the tumor microenvironment that affect cancer immunity. The purinergic signaling pathways have been shown to play an important role in the development and progression of cancer. CD39 and CD73 are ectonucleotidases responsible for breaking down ATP or ADP into adenosine, which regulates immunosuppression in various types of cancer. These enzymes have been studied as a potential therapeutic target in immunotherapy, and recent research suggests a correlation between ectonucleotidases and clinical outcomes in cancer.Prostate cancer is the most diagnosed cancer in men, after non-melanoma skin tumors, and is the second leading cause of death in men in the world. Despite having long survival periods, patients often receive excessive or insufficient treatment. Within this complex landscape, the adenosine/CD73 pathway plays a crucial role. Therefore, this review aims to highlight new findings on the potential role of purinergic signaling in cancer treatment and emphasizes the importance of anti-CD73 as a pharmacological strategy for prostate cancer therapy.","PeriodicalId":5,"journal":{"name":"ACS Applied Materials & Interfaces","volume":null,"pages":null},"PeriodicalIF":8.3000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Materials & Interfaces","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fimmu.2024.1455469","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Purines and pyrimidines are signaling molecules in the tumor microenvironment that affect cancer immunity. The purinergic signaling pathways have been shown to play an important role in the development and progression of cancer. CD39 and CD73 are ectonucleotidases responsible for breaking down ATP or ADP into adenosine, which regulates immunosuppression in various types of cancer. These enzymes have been studied as a potential therapeutic target in immunotherapy, and recent research suggests a correlation between ectonucleotidases and clinical outcomes in cancer.Prostate cancer is the most diagnosed cancer in men, after non-melanoma skin tumors, and is the second leading cause of death in men in the world. Despite having long survival periods, patients often receive excessive or insufficient treatment. Within this complex landscape, the adenosine/CD73 pathway plays a crucial role. Therefore, this review aims to highlight new findings on the potential role of purinergic signaling in cancer treatment and emphasizes the importance of anti-CD73 as a pharmacological strategy for prostate cancer therapy.

查看原文本刊更多论文

嘌呤能信号在癌症治疗中的潜在作用：前列腺癌抗 CD73 策略展望

嘌呤和嘧啶是肿瘤微环境中影响癌症免疫的信号分子。嘌呤能信号通路已被证明在癌症的发生和发展中起着重要作用。CD39 和 CD73 是外切核苷酸酶，负责将 ATP 或 ADP 分解为腺苷，从而调节各种类型癌症的免疫抑制。这些酶已被作为免疫疗法的潜在治疗靶点进行研究，最近的研究表明，外切核苷酸酶与癌症的临床结果之间存在相关性。前列腺癌是继非黑色素瘤皮肤肿瘤之后被诊断出的最常见的男性癌症，也是全球男性第二大死因。尽管前列腺癌的生存期很长，但患者接受的治疗往往过多或不足。在这种复杂的情况下，腺苷/CD73 通路发挥着至关重要的作用。因此，本综述旨在重点介绍嘌呤能信号转导在癌症治疗中的潜在作用的新发现，并强调抗 CD73 作为前列腺癌治疗药物策略的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Materials & Interfaces 工程技术-材料科学：综合

CiteScore

16.00

自引率

6.30%

发文量

4978

审稿时长

1.8 months

期刊介绍： ACS Applied Materials & Interfaces is a leading interdisciplinary journal that brings together chemists, engineers, physicists, and biologists to explore the development and utilization of newly-discovered materials and interfacial processes for specific applications. Our journal has experienced remarkable growth since its establishment in 2009, both in terms of the number of articles published and the impact of the research showcased. We are proud to foster a truly global community, with the majority of published articles originating from outside the United States, reflecting the rapid growth of applied research worldwide.